Johnson & Johnson Strengthens its Biosurgical Position by Acquiring Omrix

By Sally Mardikian PhD

Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)

Published: 24 Nov-2008

DOI: 10.3833/pdr.v2008.i102.111     ISSN: 1756-7874

Section: Mergers & Acquisitions



Johnson & Johnson (J&J) has gained a series of innovative biosurgical products with its acquisition of Omrix, its partner of five years, for US$438 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details